Auro Laboratories Ltd (AUROLAB) — shareholding pattern, promoter holding, financials and share price
About Auro Laboratories Ltd (AUROLAB)
Auro Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as AUROLAB and on the BSE under scrip code 530233. Its ISIN is INE292C01011.
Incorporated in 1989, Auro Laboratories Ltd is in the business of Bulk Drugs [1]
Auro Laboratories Ltd specializes in the manufacturing of generic Active Pharmaceutical Ingredients (APIs), with a primary focus on anti-diabetic medications like Metformin HCL.
The company is serving international markets, exporting a significant portion of its production to regions such as South East Asia, the Middle East, and Europe.
Listed peers in Pharmaceuticals: Bio Medica Laboratories Ltd, Panchsheel Organics Ltd, Speciality Medicines Ltd, Quest Laboratories Ltd, Natural Capsules Ltd, Kimia Biosciences Ltd.
Valuation & Returns
10 Jul 2026At ₹251.5 a share on 10 Jul 2026, Auro Laboratories Ltd (AUROLAB) was valued at a price-to-earnings ratio of 44.4x against an industry P/E of 36.41x and a price-to-book of 3.65x on a book value of ₹68.94 per share as of Mar 2025. Solomo computes return on equity of 8.22% and return on capital employed of 10.57% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 44.4x
- Industry P/E
- 36.41x
- P/B
- 3.65x
- EPS (TTM)
- ₹5.66
- Book value / share
- ₹68.94
- ROE
- 8.22%
- ROCE
- 10.57%
- ROA
- 3.56%
- Debt / equity
- 0.99x
- Dividend yield
- 0%
- EBITDA margin
- 31.03%
- 52-week range
- ₹159 – ₹317
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2025In the year ended Mar 2025, Auro Laboratories Ltd (AUROLAB) reported revenue of ₹19.4 crore, net profit of ₹1.84 crore and earnings per share of ₹2.95. Figures are consolidated, as filed with the exchanges.
In the quarter ended Sep 2025, revenue was ₹8.84 crore and net profit ₹0.72 crore (consolidated).
| Metric | Mar 2025 |
|---|---|
| Revenue (₹ cr) | 19.4 |
| Net profit (₹ cr) | 1.84 |
| EPS (₹) | 2.95 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -4.53% | -15.03% | -27.48% | -63.83% |
| Profit growth | 8.51% | -14.63% | -13.54% | -76.38% |
| Stock price CAGR | 24% | 6% | 43% | -21% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 52.4% of Auro Laboratories Ltd (AUROLAB) (up 0.22 pp QoQ) and domestic institutional investors (DII) hold 0.01%. Market capitalisation was ₹157 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: KIRTILABEN JAYANTILAL MEHTA 3.13%, SAMIR JITENDRA JAVERI 1.63%, SHIKHA LOHIA 1.54%, RAVI PARIMAL SHAH 1.45%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 52.4% | - | - | 0.01% | 47.6% |
| Mar 2026 | 52.18% | - | - | 0.01% | 47.82% |
| Dec 2025 | 52.18% | - | - | 0.01% | 47.82% |
| Sep 2025 | 52.18% | - | - | 0.01% | 47.82% |
| Jun 2025 | 52.18% | - | - | 0.01% | 47.82% |
| Mar 2025 | 52.18% | - | - | 0.01% | 47.82% |
| Dec 2024 | 52.15% | - | - | 0.01% | 47.85% |
| Sep 2024 | 52.15% | - | - | 0.01% | 47.85% |